Overview

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Status:
Withdrawn

Trial end date:
2020-10-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess safety, tolerability, preliminary efficacy, and PK of TAK-671 in participants with COVID-19.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda